Vilon

Also known as Khavinson-type bioregulator (catalogue name).

Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.

Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.

At-a-glance profile

Classification: Short synthetic ‘cytogen / bioregulator’ peptide (research literature)
Approval status: Research only · Not approved for human use
Research status: Investigational / reference listing.
Molecular formula: Insufficient reliable evidence identified.
Molecular weight: Insufficient reliable evidence identified.
Sequence: Lys-Glu dipeptide bioregulator.
Primary biological target: Insufficient reliable evidence identified.
Half-life: Insufficient reliable evidence identified.
Routes investigated: Insufficient reliable evidence identified.
Human evidence level: D — Primarily animal / preclinical evidence

What is it?

A very short peptide sold under the trade-style name Vilon, often marketed as an organ-specific ‘cytogen’. Not an approved immune / ageing medicine. Not sold.

Mechanism of action

Proposed gene-expression or tissue-specific peptide signalling is not established as a registered therapy.

Unproven outside experimental literature.

What is it being studied for?

Experimental immune / ageing bioregulator literature

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: D · Primarily animal / preclinical evidence

Human research

No registration-quality human programme as a consumer peptide product.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

Scattered preclinical or analogue literature; catalogue vials are not the same as published reagents.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Safety

Unknown impurities, dose error, and infection risk dominate grey-market injectables.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Not for human use. Not for compounding outside a licensed pharmacy and lawful prescription.

Regulatory status

Not an approved finished medicine in typical grey-market vial form.

Cellular Sequence does not sell this as a vial, tablet, oil, or injectable. Educational encyclopaedia listing only.

Citations

[1] Encyclopaedia note
Encyclopaedia note

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Healthy Ageing · Compare peptides